Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Research & Development (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Research & Development for 4 consecutive years, with $22.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 17.24% to $22.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $105.3 million, a 5.17% increase, with the full-year FY2024 number at $107.2 million, up 15.68% from a year prior.
  • Research & Development was $22.5 million for Q3 2025 at Century Therapeutics, down from $26.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $29.4 million in Q4 2024 to a low of $21.2 million in Q1 2022.
  • A 4-year average of $24.9 million and a median of $24.9 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 31.75% in 2024, then decreased 17.24% in 2025.
  • Century Therapeutics' Research & Development stood at $25.6 million in 2022, then fell by 12.86% to $22.3 million in 2023, then surged by 31.75% to $29.4 million in 2024, then dropped by 23.29% to $22.5 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Research & Development are $22.5 million (Q3 2025), $26.9 million (Q2 2025), and $26.6 million (Q1 2025).